z-logo
open-access-imgOpen Access
Ultrabright NIR‐II Emissive Polymer Dots for Metastatic Ovarian Cancer Detection
Author(s) -
Zhou Xiaobo,
Liu Qiyu,
Yuan Wei,
Li Zhenhua,
Xu Yuliang,
Feng Wei,
Xu Congjian,
Li Fuyou
Publication year - 2021
Publication title -
advanced science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.388
H-Index - 100
ISSN - 2198-3844
DOI - 10.1002/advs.202000441
Subject(s) - fluorescence , ovarian cancer , fluorophore , ethylene glycol , fluorescence lifetime imaging microscopy , chemistry , metastasis , cancer , materials science , medicine , optics , organic chemistry , physics
Intraoperative diagnosis of metastatic tumors is of significant importance to the treatment of ovarian cancer. NIR‐II fluorescence imaging holds great promise for facile detection of tumor in situ with high sensitivity and resolution. Herein, a kind of NIR‐II fluorescent polymer dots (NIR‐II Pdots) with high brightness is developed for real‐time detection of metastatic ovarian cancer via NIR‐II fluorescence imaging. The NIR‐II Pdots are constructed via the self‐assembly of NIR‐II emissive aggregation induced emission luminogens (NIR‐II AIEgens) and poly (styrene)‐graft‐poly(ethylene glycol) in water. Such NIR‐II Pdots show very high fluorophore contents of nearly 30% and high quantum yield of 5.4% at emission maximum near 1020 nm. Further modification of the NIR‐II Pdots with targeting peptides yields NIR‐II Pdots‐GnRH, which can afford enhanced affinity of NIR‐II Pdots to ovarian cancer. Upon intravenous injection of the NIR‐II Pdots, whole‐body organs and vessels, peritoneal and lymphatic metastases of ovarian cancer are clearly visualized by NIR‐II fluorescence imaging. Under the guidance of NIR‐II fluorescence imaging, the metastatic foci with the diameter down to ≈2 mm can be facilely eliminated. The results indicate preclinical potential value of the NIR‐II Pdots for metastatic ovarian cancer detection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here